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Randomized Evaluation of Carotid




Objective: To determine whether extracranial-intracranial (EC-IC) bypass can improve cognition
over 2 years compared to best medical therapy alone in patients with symptomatic internal
carotid artery (ICA) occlusion and increased oxygen extraction fraction (OEF) on PET.
Methods: Patients underwent 15O PET and were randomized if OEF ratio was .1.13 on the
occluded side. Using blinded baseline and 2-year cognitive assessments, age-adjusted composite
z scores were generated from subtests sensitive to right/left hemisphere plus global cognitive
functioning. Multiple regression predicted 2-year cognitive change.
Results: Eighty-nine patients were enrolled; 41 had increased OEF and were randomized. Two
died, 2 were lost to follow-up, and 2 refused 2-year testing. Of the 35 remaining, 6 had ipsilateral
stroke or death, leaving 13 surgical and 16 medical patients. Controlling for age, education, and
depression, there was no difference in 2-year cognitive change between the medical and surgical
arms (95% confidence interval 20.5 to 0.5, p 5 0.9). In post hoc analysis of 26 patients with no
stroke in the follow-up period, cognitive improvement was associated with less impaired PET OEF
at baseline (p 5 0.045).
Conclusion: Cognitive improvement following bypass surgery was not superior to medical therapy
among patients with recently symptomatic carotid occlusion and increased OEF. Among those
with no recurrent stroke, less hemodynamic impairment at baseline was associated with greater
cognitive gain in both groups. Reversing cognitive impairment in hemodynamic failure remains an
open challenge.
Classification of evidence: This study provides Class II evidence that for patients with symptomatic
ICA occlusion and increased OEF on PET, EC-IC bypass compared to no bypass does not improve
cognitive function after 2 years. Neurology® 2014;82:744–751
GLOSSARY
CBF 5 cerebral blood flow; CES-D 5 Center for Epidemiological Studies–Depression; CI 5 confidence interval; COSS 5
Carotid Occlusion Surgery Study; EC-IC 5 extracranial-intracranial; ICA 5 internal carotid artery; OEF 5 oxygen extraction
fraction; PCA 5 principal components analysis; RECON 5 Randomized Evaluation of Carotid Occlusion and Neurocognition.
Cognitive impairment in carotid artery disease is thought to be due in part to cerebrovascular
hemodynamic failure independent of infarction,1–4 making it a potentially reversible cause of
dementia. Evidence of reversibility has been supported by case reports and small noncontrolled
studies,5 but the treatment of cognitive impairment in this population has never been tested in a
randomized controlled trial. The Randomized Evaluation of Carotid Occlusion and Neuro-
cognition (RECON), an ancillary study of the Carotid Occlusion Surgery Study (COSS), was a
National Institute of Neurological Disorders and Stroke–sponsored, phase III, multicenter,
randomized, controlled, open-label (blinded outcome) clinical trial that ran from November
2004 to June 2012. RECON tested the hypothesis that extracranial-intracranial (EC-IC) sur-
gical bypass plus best medical therapy could improve or preserve cognitive function at 2 years in
patients with symptomatic internal carotid artery (ICA) occlusion and stage II hemodynamic
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failure (increased oxygen extraction fraction
[OEF]) compared with best medical therapy
alone. Although the parent study, COSS, failed
to show a difference in rate of subsequent stroke
and death between the 2 treatment arms6 and
was terminated early for futility, thus discontin-
uing RECON enrollment, RECON completed
the 2-year follow-up visits for the already
randomized RECON patients. We recently
reported that cognitive impairment in our
RECON patients at baseline was independently
correlated with increased OEF on PET,4 sup-
porting the hemodynamic hypothesis of cogni-
tive impairment upon which the RECON
intervention trial was based. We report the
main results of the RECON trial after the
2-year follow-ups were completed.
METHODS Research question. Can EC-IC bypass, when
added to best medical therapy, improve cognitive function after
2 years in patients with symptomatic ICA occlusion and
increased OEF on PET, compared with best medical therapy
alone? Class of evidence assigned was Class II.
Subjects. Patients were enrolled into RECON between 2005
and 2010 at academic medical centers if they met the following
inclusion criteria: 1) age 18 to 85, 2) complete ICA occlusion
(confirmed by catheter angiography prior to randomization), 3)
hemispheric TIA or minor stroke in the territory of the carotid
occlusion within 120 days prior to enrollment, 4) Barthel Index
$12/20 at the time of enrollment (after the qualifying event), 5)
education level .4 years, 5) no prior diagnosis of dementia.
Nonatherosclerotic causes of carotid occlusion were excluded
based on all available clinical data. TIA was defined clinically as
having no residual neurologic deficit after 24 hours. MRI was not
available in all patients and so was not used in the definition of
TIA. Once enrolled, patients were then eligible for randomization
if they had asymmetrically increased OEF by PET, with an OEF
ratio .1.13 on the side of occlusion, indicating stage II hemo-
dynamic failure. Those who had #1.13 OEF ratio were not
randomized and went no further in the study. Those randomized
to the surgical arm also underwent PET at 30 days after surgery.
The PET threshold of 1.13 was determined by the St. Louis
Carotid Occlusion Study, which examined thresholds of OEF
associated with a higher rate of subsequent stroke.7 A copy of
the full protocol is available upon request.
Randomization and masking. The 1:1 randomization was
performed as part of the parent clinical trial (COSS) using per-
muted blocks with stratification for clinical site using the SAS
uniform random number generator (RANUNI). Cognitive as-
sessments were done by testers blinded to the treatment arm as
described below.
Standard protocol approvals, registrations, and patient
consents. All patients signed informed consent. The study was
approved by the Columbia University Institutional Review
Board. ClinicalTrials.gov identifier: NCT00390481.
Neurocognitive testing. At baseline and at 2 years, patients
underwent a 1-hour neurocognitive battery consisting of
14 standardized neuropsychological tests, administered by a
neuropsychologist or trained technician blinded to the patient’s
treatment arm. The battery was designed to assess left hemisphere
function, right hemisphere function, and global function.
Published age-adjusted normative data were available for all
tests.8–17 All patients were administered all 14 neurocognitive
tests. The order of test administration remained constant,
accommodating the delays required for recall intervals
and minimizing stimulus interference in memory tasks. The
test battery is summarized in table 1. Patients also completed
the Center for Epidemiological Studies–Depression (CES-D)
scale.
Because hemodynamic failure in the hemisphere ipsilateral to
the symptomatic carotid occlusion was hypothesized to affect pre-
dominantly functions associated with that hemisphere, as well as
global cognitive function that would also depend on the integrity
of that hemisphere, composite scores were generated for each
patient based on the hemisphere of interest. We first transformed
the raw test scores for each patient into z scores for each test in the
battery,18 derived from the published norms. We then calculated
a composite z score19,20 based on the average z score for the
appropriate set of tests for each patient (sum of the relevant z
scores divided by the number of tests included). For patients with
left carotid occlusion, “left hemisphere” and “global” test scores
were used; for patients with right carotid occlusion, “right hem-
isphere” and “global” test scores were used. To test the assump-
tions of our hypothesis that hemisphere-specific plus global
composite scores were associated with cognitive impairment in
this patient population, we also performed a principal compo-
nents analysis (PCA)21 of baseline neurocognitive test scores of all
enrolled patients to derive a data-driven composite score that
would explain the greatest proportion of variance in baseline cog-
nitive function.
Statistical analysis. Patients who reached a COSS endpoint
(ipsilateral stroke or death) during the 2-year follow-up period
were censored from analysis. A multivariable linear regression
was performed, with change in composite neurocognitive
z score over 2 years as the dependent variable. The primary
independent variable of interest was treatment arm (surgical vs
medical). A power calculation based on definitions of small,
Table 1 Summary of neurocognitive tests by hemisphere specificity
Neurocognitive test Presumed hemisphere specificity
Trail Making Test part A Global
Trail Making Test part B Global
Digit Span Global
Digit Symbol Global
Boston Naming Test Left
Repetition (Boston Diagnostic Aphasia Examination) Left
Hopkins Verbal Memory Test–Revised Left
Word fluency (Controlled Oral Word Association) Left
Rey figure (copy) Right
Rey figure (delayed recall) Right
Line bisection Right
Target cancellation Right
Grooved pegboard (“affected” hand) Left/right
Grooved pegboard (“unaffected” hand) Global
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moderate, and large effect size22 determined that we would need a
total of .30 patients randomized to identify a large effect size of
0.8 SD for the primary outcome. Age, education level (#8th
grade, 9–12th grade [high school], $13 years [some college])
and depression (as measured by the CES-D at 2 years) were
entered into the model as covariates in a prespecified primary
regression analysis. A post hoc univariate regression was also
performed to identify all variables that had a significant
association with cognitive z score change, with an adjustment
for baseline score. Covariates with p , 0.05 in the univariate
analyses were added one at a time in a forward variable
selection process; only covariates with p , 0.05 after adjusting
for other factors in the final multivariable model were retained.
The same univariate analyses were also performed using the PCA-
derived composite neurocognitive z score as the dependent
variable.
RESULTS Eighty-nine patients (27 women, mean
age 576 9.3) from 19 RECON centers were enrolled
in the study. Of those, 41 had PET OEF ratio.1.13
and were randomized to the surgical (n 5 19) vs
medical (n 5 22) treatment arm. Two died (medical
arm), 2 were lost to follow-up (surgical arm), and 2
refused 2-year testing (medical arm). Of the 35
remaining patients, 6 had COSS endpoints
(ipsilateral stroke or death: 4 in the surgical group,
2 in the medical group), leaving 13 in the surgical
group and 16 in the medical group for full analysis
(figure 1).
Table 2 shows baseline characteristics for the 29
patients in the analysis cohort. There were no differ-
ences in demographic, clinical, or radiologic character-
istics between the groups. The average neurocognitive
composite z score at baseline across all patients was 1.2
SD below the age- and education-adjusted mean
(range23.7 to20.3); there was no difference in cog-
nitive scores between groups at baseline. Although no
patients had a diagnosis of dementia at time of enroll-
ment, nearly all patients had scores below the means
for their age, indicating mild cognitive impairment in
this group. No workup for dementia was pursued since
the patients were functioning normally prior to enroll-
ment in the study. Controlling for age, education,
depression, and baseline composite neurocognitive z
score as prespecified for the study, there was no differ-
ence in change in composite z score between the sur-
gical and medical groups over the 2-year follow-up
period (point estimate 0.02, 95% confidence interval
[CI] 20.50 to 0.54, p 5 0.93; table 3). Of note, the
point estimate (mean) was nearly 0. Individual cogni-
tive change scores are illustrated in figure 2. Three
patients—2 in the nonsurgical arm and 1 in the sur-
gical arm—had contralateral strokes during the 2-year
period, represented by dashed lines in the figure. They
were included as per our protocol in the primary
analysis.
The OEF PET ratio in the surgical group had a
statistically significant decrease from an average of
1.24 at baseline to 1.14 at 30 days postoperatively
(t 5 2.8, p 5 0.013). Only 3 of the 13 surgical
patients had 30-day PET OEF ratios #1.13, the
COSS threshold for randomization into the study,
and none of the 13 achieved OEF ratio ,1.067,
the upper limit of normal for the COSS cohort over-
all. The patency rate for the bypass was 98% at the
30-day postoperative point and 96% at the last
follow-up in the COSS cohort, based on low-
resistance, high-flow signal by Doppler.23
We also performed a post hoc regression analysis
of all collected variables against cognitive change
among all patients, taking as our dataset only patients
who had no stroke (ipsilateral or contralateral) in the
2-year follow-up period. We focused on this set of
patients to minimize the potential cognitive effects
of a new stroke. The only variable that was associated
with greater improvement in 2-year composite
Figure 1 Study design flow diagram
COSS 5 Carotid Occlusion Surgery Study; endpts 5 endpoints; OEF 5 oxygen extraction fraction.
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neurocognitive z score was a less impaired PET ratio at
baseline, which remained significant in the multiple
regression analysis (t 5 21.73, p 5 0.045, 95%
CI 5 23.41 to 20.042; see table 3). When the alter-
native, PCA-derived composite neurocognitive z score
was used in the univariate analysis, PET ratio was sig-
nificantly associated with cognitive change, as well as
qualifying event type: TIA, indicating good concordance
with our primary composite test grouping. It is possible
that individual test battery components may have cor-
related with some of our independent variables includ-
ing the treatment arm, but this analysis was not
prespecified and will be explored separately.
DISCUSSION Our main finding for this phase III
randomized controlled trial was that there was no
evidence to support superiority of EC-IC bypass
surgery plus best medical therapy in preserving or
improving cognition over medical therapy alone in
patients with recently symptomatic carotid artery
occlusion and stage II hemodynamic failure. There
was a range of cognitive change scores over the
2-year follow-up period, but the change did not
depend on which treatment was received.
The hemodynamic hypothesis that formed the
premise for this trial was supported most compel-
lingly by studies in which cognitive impairment was
found in the absence of frank stroke. An early study
reported cognitive impairment in 39 cases with cere-
bral or retinal TIAs but no stroke on MRI.24 No
hemodynamic measurements were made in that
study. A more recent study showed that, among
333 patients with asymptomatic high-grade carotid
stenosis, cognitive impairment was present compared
to those without carotid stenosis, and was associated
with impaired cerebrovascular reactivity as measured
by transcranial Doppler breath-holding index.3
Finally, in a baseline analysis of our own RECON
patients, among 71 with complete clinical data and
adequate PET imaging, we showed that increased
OEF ratio .1.13 was independently associated with
cognitive impairment in the subset of patients with
TIA as qualifying event.4 Taken together, these re-
sults suggest that the substrate upon which the surgi-
cal intervention was intended to work was present,
supporting the notion that reversing the hemody-
namic failure could potentially reverse cognitive
impairment. An alternative hypothesis would be that
the cognitive impairment was due to hemodynami-
cally induced, fixed injury that would not be amena-
ble to reversal by improvement in hemodynamics.
Revascularization surgery has been reported to
improve cognitive impairment in carotid artery stenosis
and occlusion, although reported results have been var-
iable and appear only in nonrandomized studies.25–28
Many early studies included nonstandardized measure-
ment of cognition, varying clinical states among pa-
tients (stroke, TIA, asymptomatic), and no comparison
group. Two reports did include quantitative blood flow
measurements. First, in a single case of bilateral ICA
occlusions presenting with subacute onset of severe
behavioral and cognitive decline, neuropsychological
improvement was demonstrated after EC-IC bypass
that was associated with significant increases in cerebral
blood flow (CBF) and metabolism measured by quan-
titative CBF and PET.2 Second, in a larger case series,
25 patients with unilateral carotid occlusion and poor
neuropsychological performance underwent EC-IC
bypass, and were shown to have cognitive improve-
ment associated with increased CBF, improved cere-
bral vasomotor reactivity, and improved OEF as
measured by PET.5
Table 2 Baseline characteristics: Medical vs surgical groups
Medical (n 5 16) Surgical (n 5 13) p Valuea
Age, y, mean (SD) 57.3 (8) 56.7 (10) 0.74
Sex, n (%)
Male 12 (75) 11 (85) 0.66
Female 4 (25) 2 (15)
Handedness, n (%)
Left 3 (19) 0 (0) 0.23
Right 13 (81) 13 (100)
Education, n (%)
8th grade 0 (0) 1 (8) 0.18
High school 11 (69) 5 (38)
College 5 (31) 7 (54)
ICA side, n (%)
Left 7 (44) 8 (62) 0.46
Right 9 (56) 5 (38)
Contralateral stenosis <50%b
No 6 (36) 1 (8) 0.09
Yes 9 (64) 11 (92)
Qualifying event type, n (%)
Stroke 7 (44) 5 (38) 1.00
TIA 9 (56) 8 (62)
PET ratio,c mean (SD) 1.2 (0.06) 1.2 (0.15) 0.5
Previous stroke, n (%)
No 11 (69) 9 (69) 1.00
Yes 5 (31) 4 (31)
CES-D base, mean (SD) 18 (12) 18 (9) 0.84
Base z score, mean (SD) 21.5 (0.8) 20.9 (0.8) 0.09
Abbreviations: CES-D 5 Center for Epidemiological Studies–Depression; ICA 5 internal
carotid artery.
ap Values from t test with mean and SD, Wilcoxon rank sum test with median and inter-
quartile range, or Fisher exact test.
bOne missing in each treatment group.
c PET ratio 5 hemispheric ratio of oxygen extraction fraction ipsilateral-to-contralateral.
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Table 3 Univariate analysis of all independent variables for the 26 patients with no ipsilateral or contralateral
stroke
Variable Estimate SE 95% CI p Value
Treatment (medical 5 0, surgical 5 1) 0.087 0.20 20.32 to 0.50 0.67
Age 20.011 0.011 20.035 to 0.012 0.33
Education (0 for 8th grade, 1 for high school, 2 for college) 0.15 0.19 20.25 to 0.54 0.45
CES-D 2-year 20.0072 0.013 20.034 to 0.020 0.59
Sex (male 5 0, female 5 1) 20.012 0.25 20.52 to 0.50 0.96
Contralateral stenosis <50% (no 5 0, yes 5 1)a (n 5 27) 0.34 0.25 20.17 to 0.86 0.18
Handedness (left 5 0, right 5 1) 0.19 0.36 20.56 to 0.94 0.60
ICA side (left 5 0, right 5 1) 20.096 0.20 20.50 to 0.31 0.63
PET ratiob 21.73 0.82 23.41 to 20.042 0.045
Previous stroke (no 5 0, yes 5 1) 20.32 0.20 20.73 to 0.091 0.12
Change in CES-D 20.0064 0.011 20.030 to 0.017 0.58
Qualifying event type (stroke vs TIA)c 0.35 0.19 20.046 to 0.74 0.081
Abbreviations: CES-D 5 Center for Epidemiological Studies–Depression; CI 5 confidence interval; ICA 5 internal carotid
artery.
aStenosis 5 contralateral ICA , 50%.
bPET ratio 5 hemispheric ratio of oxygen extraction fraction ipsilateral-to-contralateral. Significant after multivariable analysis.
c Event type 5 qualitfying (entry) event.
Figure 2 Individual composite cognitive change scores by treatment group
Dashed lines indicate patients with contralateral stroke during the follow-up period. Red line represents mean change score
for each group.
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The cognitive outcomes in RECON were based
on randomization against a control arm, which had
never been done previously. There were limitations
to the study, however. The first was the study’s small
sample size, resulting from early termination of the
parent trial. Although the final number of subjects for
RECON met our prestudy power calculation for
detecting a large effect size (a difference of 0.8 SD
in composite cognitive change score between treat-
ment arms), it is possible that greater numbers of
patients may have demonstrated a small or moderate
superiority of one treatment arm or the other,
although with the point estimate near zero this would
have been unlikely. The 95% CI for cognitive change
as shown in table 3 was20.5 to 0.5 SD, the limits of
a moderate effect size.22 A second limitation was the
presence of other variables that could have affected
cognitive performance at the time of testing, includ-
ing use of sedative or anticholinergic medications,
medical illnesses, or sleep deprivation. We know that
prevalence of sedatives was low (2 of 29 in the fully
evaluated cohort), and there was no change from
baseline to 2-year follow-up, so there would be low
likelihood of bias. In addition, stroke itself might have
affected cognitive function. In our cohort, 9 patients
had previous strokes and 12 had stroke as qualifying
event. Leukoaraiosis was not measured. Because the
stroke numbers were equally distributed between
treatment arms, however, the randomization process
should have mitigated any bias that might have been
present with respect to our treatment outcomes. Fur-
thermore, previous stroke was not a predictor for cog-
nitive decline, either in the current cohort (table 3) or
in our previously published article on baseline corre-
lates of cognitive dysfunction, in which OEF but not
previous strokes correlated with (mild) cognitive
impairment.4 A third limitation may have been the
relatively modest reduction in OEF ratio achieved by
the bypass in our RECON cohort. Despite an out-
standing surgical result in terms of graft patency, and
a statistically significant improvement in OEF, only 3
of the 13 patients in the surgical arm had postopera-
tive OEF ratio #1.13, the PET threshold for study
randomization, and none of them achieved OEF ratio
,1.067, the upper limit of normal for the overall
COSS cohort. Thus, our primary hypothesis regard-
ing cognitive gains following hemodynamic improve-
ment may not have been adequately tested. While the
improvement in OEF from EC-IC bypass in the
entire COSS surgical group was sufficient to reduce
the subsequent risk of ipsilateral stroke in those who
did not have stroke as a surgical complication,6 the
threshold for cognitive improvement might be
greater. In an addition, hemodynamics may have
improved over time in the medical arm,29 perhaps
due to gradual improvement in collateral flow.
Finally, our findings may be related to the aggressive
medical management in both arms, including blood
pressure control and administration of statins. Nota-
bly, neither the nonsurgical nor the surgical group in
our cohort had cognitive deterioration over 2 years
despite entering the study with some cognitive dys-
function. Despite recent concerns that statins may
worsen cognitive function,30,31 we found no evidence
for this in our study. Rather, statins32–34 as well as
blood pressure management35–37 appear to positively
affect cognitive status and have known hemodynamic
effects.38–40 Two recent surgical trials, RECON’s
parent trial COSS and the Stenting and Aggressive
Medical Management for Preventing Recurrent
stroke in Intracranial Stenosis (SAMMPRIS) study,
failed to show superiority of an intervention in part
due to better than expected outcomes in the medical
arm. Although the outcomes in these 2 trials were
recurrent stroke, it is plausible that medical therapy
plays an important role in treatment of cognitive
impairment.
Given the evidence from prior studies that cere-
brovascular hemodynamic status is a determinant of
cognitive function, it is reasonable to include cogni-
tive outcomes in future trials of carotid revasculariza-
tion, and to pursue other reperfusion interventions
with greater hemodynamic efficacy and lower mor-
bidity. Further research is needed to determine
thresholds of cerebral hemodynamic failure that per-
mit or promote cognitive improvement. For the pre-
sent, however, it appears that medical therapy,
including the consistent use of statins and antihyper-
tensives, may help preserve cognition in this patient
population; there is no evidence that surgical inter-
vention with EC-IC bypass is better than medical
therapy.
AUTHOR CONTRIBUTIONS
R.S. Marshall: study conceptualization and design, data review, manu-
script writing. J.R. Festa: manuscript editing, neuropsychological battery
design. Y.K. Cheung: manuscript editing, statistical design and analysis.
M.A. Pavol: manuscript review and revision, neuropsychological battery
review. C.P. Derdeyn: PET data analysis, manuscript review and revision.
W.R. Clarke: study design, data analysis, manuscript review and revision.
T.O. Videen: PET study design and analysis, manuscript review and revi-
sion. R.L. Grubb: neurosurgical design input, manuscript review and
revision. K. Slane: data preparation and analysis, manuscript review.
W.J. Powers: study conceptualization, manuscript review and revision.
R.M. Lazar: study design, conceptualization, neuropsychological battery
design, manuscript review and revision.
STUDY FUNDING
Supported by NINDS NS048212 (Dr. Marshall), NINDS NS42167
(Dr. Powers), and 5U01NS041895 (Dr. Clarke).
DISCLOSURE
R. Marshall is supported by the National Institute of Neurological Dis-
orders and Stroke NS048212. J. Festa is supported by the National Insti-
tute of Neurological Disorders and Stroke NS048212. Y. Cheung is
supported by the National Institute of Neurological Disorders and Stroke
Neurology 82 March 4, 2014 749
NS048212. M. Pavol is supported by the National Institute of Neurolog-
ical Disorders and Stroke NS048212. C. Derdeyn is supported by the
National Institute of Neurological Disorders and Stroke NS048212 and
NS42167. W. Clarke is supported by the National Institute of Neurological
Disorders and Stroke 5U01NS041895. T. Videen is supported by the
National Institute of Neurological Disorders and Stroke NS42167.
R. Grubb is supported by the National Institute of Neurological Disorders
and Stroke NS42167. K. Slane is supported by the National Institute of
Neurological Disorders and Stroke NS048212. W. Powers is supported
by the National Institute of Neurological Disorders and Stroke NS42167.
R. Lazar is supported by the National Institute of Neurological Disorders
and Stroke NS048212. Go to Neurology.org for full disclosures.
Received June 11, 2013. Accepted in final form October 18, 2013.
REFERENCES
1. Silvestrini M, Paolino I, Vernieri F, et al. Cerebral hemo-
dynamics and cognitive performance in patients with
asymptomatic carotid stenosis. Neurology 2009;72:
1062–1068.
2. Tatemichi TK, Desmond DW, Prohovnik I, Eidelberg D.
Dementia associated with bilateral carotid occlusions: neu-
ropsychological and haemodynamic course after extracra-
nial to intracranial bypass surgery. J Neurol Neurosurg
Psychiatry 1995;58:633–636.
3. Balucani C, Viticchi G, Falsetti L, Silvestrini M. Cerebral
hemodynamics and cognitive performance in bilateral asymp-
tomatic carotid stenosis. Neurology 2012;79:1788–1795.
4. Marshall RS, Festa JR, Cheung YK, et al. Cerebral hemo-
dynamics and cognitive impairment: baseline data from
the RECON trial. Neurology 2012;78:250–255.
5. Sasoh M, Ogasawara K, Kuroda K, et al. Effects of EC-IC
bypass surgery on cognitive impairment in patients with
hemodynamic cerebral ischemia. Surg Neurol 2003;59:
455–460; discussion 460–453.
6. Powers WJ, Clarke WR, Grubb RL Jr, Videen TO,
Adams HP Jr, Derdeyn CP. Extracranial-intracranial
bypass surgery for stroke prevention in hemodynamic cere-
bral ischemia: the Carotid Occlusion Surgery Study ran-
domized trial. JAMA 2011;306:1983–1992.
7. Grubb RL Jr, Derdeyn CP, Fritsch SM, et al. Importance
of hemodynamic factors in the prognosis of symptomatic
carotid occlusion. JAMA 1998;280:1055–1060.
8. Lezak MD Howiezon DB, Loring DW, eds. Neuropsy-
chological Assessment, 4th ed. Oxford: Oxford University
Press; 2004.
9. Meyers JE, Meyers K. The Meyers Scoring System for the
Rey Complex Figure and the Recognition Trial: Profes-
sional Manual. Odessa, FL: Psychological Assessment Re-
sources; 1995.
10. Brandt J, Benedict RHB. Hopkins Verbal Learning Test:
revised. Odessa, FL: Psychological Assessment Resources;
2001.
11. Binder J, Marshall R, Lazar R, Benjamin J, Mohr JP. Dis-
tinct syndromes of hemineglect. Arch Neurol 1992;49:
1187–1194.
12. Mitrushina MBK, Razani J, D’Elia LF. Handbook of Nor-
mative Data for Neuropsychological Assessment. Oxford:
Oxford University Press; 2005.
13. Goodglass H, Kaplan EF. Assessment of Aphasia and
Related Disorders, 2nd ed. Philadelphia: Lea & Febiger;
1983.
14. Zec RF, Burkett NR, Markwell SJ, Larsen DL. Normative
data stratified for age, education, and gender on the Bos-
ton Naming Test. Clin Neuropsychol 2007;21:617–637.
15. Wechsler D. Wechsler Adult Intelligence Scale, 3rd ed.
San Antonio, TX: Harcourt Assessment; 1997.
16. Ruff RM, Parker SB. Gender- and age-specific changes in
motor speed and eye hand coordination in adults: norma-
tive values for the finger tapping and grooved pegboard
tests. Percept Mot Skills 1993;76:1219–1230.
17. Tombaugh TNKJ, Reees L. Normative data stratified by
age and education for two measures of verbal fluency: FAS
and animal naming. Arch Clin Neuropsychol 1999;14:
167–177.
18. Strauss E, Sherman EMS, Spreen O, eds. A Compendium
of Neuropsychologcial Tests: Administration, Normas,
and Commentary, 3rd ed. New York: Oxford University
Press; 2006.
19. Wilson RS, Beckett LA, Bennett DA, Albert MS,
Evans DA. Change in cognitive function in older persons
from a community population: relation to age and Alz-
heimer disease. Arch Neurol 1999;56:1274–1279.
20. Newman MF, Kirchner JL, Phillips-Bute B, et al. Longi-
tudinal assessment of neurocognitive function after
coronary-artery bypass surgery. N Engl J Med 2001;344:
395–402.
21. Tabachnick B, Fidell LS. Using Multivariate Statistics,
2nd ed. New York: Harper Collins Publishers; 1989.
22. Cohen J. Statistical Power Analysis for the Behavioral Sci-
ences, 2nd ed. Hillsdale, NJ: Lawrence Erlbaum Associ-
ates; 1988.
23. Grubb RL Jr, Powers WJ, Clarke WR, Videen TO,
Adams HP Jr, Derdeyn CP. Surgical results of the carotid
occlusion surgery study. J Neurosurg 2013;118:25–33.
24. Bakker FC, Klijn CJ, Jennekens-Schinkel A, van der
Tweel I, Tulleken CA, Kappelle LJ. Cognitive impairment
in patients with carotid artery occlusion and ipsilateral
transient ischemic attacks. J Neurol 2003;250:1340–
1347.
25. Drinkwater JE, Thompson SK, Lumley JS. Cerebral func-
tion before and after extra-intracranial carotid bypass.
J Neurol Neurosurg Psychiatry 1984;47:1041–1043.
26. Nielsen H, Hojer-Pedersen E, Gulliksen G, Haase J,
Enevoldsen E. Reversible ischemic neurological deficit
and minor strokes before and after EC/IC bypass surgery:
a neuropsychological study. Acta Neurol Scand 1986;73:
615–618.
27. Lal BK, Younes M, Cruz G, Kapadia I, Jamil Z,
Pappas PJ. Cognitive changes after surgery vs stenting
for carotid artery stenosis. J Vasc Surg 2011;54:691–698.
28. Yoshida K, Ogasawara K, Kobayashi M, Kubo Y,
Otawara Y, Ogawa A. Improvement and impairment in
cognitive function after carotid endarterectomy: compari-
son of objective and subjective assessments. Neurol Med
Chir 2012;52:154–160.
29. Widder B, Kleiser B, Krapf H. Course of cerebrovascular
reactivity in patients with carotid artery occlusions. Stroke
1994;25:1963–1967.
30. King DS, Wilburn AJ, Wofford MR, Harrell TK,
Lindley BJ, Jones DW. Cognitive impairment associated
with atorvastatin and simvastatin. Pharmacotherapy 2003;
23:1663–1667.
31. Agostini JV, Tinetti ME, Han L, McAvay G, Foody JM,
Concato J. Effects of statin use on muscle strength, cog-
nition, and depressive symptoms in older adults. J Am
Geriatr Soc 2007;55:420–425.
32. Cramer C, Haan MN, Galea S, Langa KM,
Kalbfleisch JD. Use of statins and incidence of dementia
750 Neurology 82 March 4, 2014
and cognitive impairment without dementia in a cohort
study. Neurology 2008;71:344–350.
33. Kishi T, Sunagawa K. Combination therapy of atorvastatin
and amlodipine inhibits sympathetic nervous system acti-
vation and improves cognitive function in hypertensive
rats. Circ J 2012;76:1934–1941.
34. Bernick C, Katz R, Smith NL, et al. Statins and cognitive
function in the elderly: the Cardiovascular Health Study.
Neurology 2005;65:1388–1394.
35. Washida K, Ihara M, Nishio K, et al. Nonhypotensive
dose of telmisartan attenuates cognitive impairment
partially due to peroxisome proliferator-activated recep-
tor-gamma activation in mice with chronic cerebral hypo-
perfusion. Stroke 2010;41:1798–1806.
36. Dregan A, Stewart R, Gulliford MC. Cardiovascular risk
factors and cognitive decline in adults aged 50 and over:
a population-based cohort study. Age Ageing 2013;42:
338–345.
37. White WB, Wolfson L, Wakefield DB, et al. Average
daily blood pressure, not office blood pressure, is associ-
ated with progression of cerebrovascular disease and cog-
nitive decline in older people. Circulation 2011;124:
2312–2319.
38. Giannopoulos S, Katsanos AH, Tsivgoulis G, Marshall RS.
Statins and cerebral hemodynamics. J Cereb Blood Flow
Metab 2012;32:1973–1976.
39. Forteza A, Romano JG, Campo-Bustillo I, et al. High-dose
atorvastatin enhances impaired cerebral vasomotor reactiv-
ity. J Stroke Cerebrovasc Dis 2012;21:487–492.
40. Walters M, Muir S, Shah I, Lees K. Effect of perindopril
on cerebral vasomotor reactivity in patients with lacunar
infarction. Stroke 2004;35:1899–1902.
Neurology® Launches Subspecialty Alerts by E-mail!
Customize your online journal experience by signing up for e-mail alerts related to your subspecialty or
area of interest. Access this free service by visiting http://www.neurology.org/site/subscriptions/etoc.xhtml
or click on the “E-mail Alerts” link on the home page. An extensive list of subspecialties, methods,
and study design choices will be available for you to choose from—allowing you priority alerts to
cutting-edge research in your field!
Enjoy Big Savings on NEW 2014 AAN Practice
Management Webinars Subscriptions
The American Academy of Neurology offers 14 cost-effective Practice Management Webinars you
can attend live or listen to recordings posted online. AAN members can purchase one webinar for
$149 or subscribe to the entire series for only $199. This is new pricing for 2014 and significantly less
than 2013—and big savings from the new 2014 nonmember price of $199 per webinar or $649 for
the subscription. Register today for these and other 2014 webinars at AAN.com/view/pmw14:
January 21 – Correct Coding for Chemodenervation
February 4 – Coding for Neurodiagnostic Procedures Made Easy
March 11 – Bundled Payments: The Role for Neurologists in New Health Care Models
Neurology 82 March 4, 2014 751
